HB Wealth Management LLC Invests $338,000 in Natera, Inc. $NTRA

HB Wealth Management LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,100 shares of the medical research company’s stock, valued at approximately $338,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Hilltop National Bank purchased a new position in Natera during the 2nd quarter valued at about $33,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Natera in the second quarter valued at approximately $36,000. Sound Income Strategies LLC grew its stake in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in Natera during the 2nd quarter worth approximately $53,000. Finally, N.E.W. Advisory Services LLC increased its holdings in Natera by 256.8% during the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after acquiring an additional 226 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Up 0.5%

Shares of NTRA stock opened at $240.34 on Friday. The business has a 50-day moving average price of $230.24 and a two-hundred day moving average price of $188.04. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The firm has a market cap of $33.24 billion, a P/E ratio of -104.95 and a beta of 1.62.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.26) earnings per share. As a group, research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of recent analyst reports. Cowen restated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. UBS Group lifted their price objective on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. BTIG Research boosted their target price on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Morgan Stanley raised their price target on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Finally, Evercore ISI lifted their price target on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average target price of $241.18.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 2,951 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $228.95, for a total transaction of $675,631.45. Following the transaction, the insider owned 123,499 shares of the company’s stock, valued at approximately $28,275,096.05. This trade represents a 2.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Herm Rosenman sold 48,419 shares of Natera stock in a transaction on Friday, December 12th. The stock was sold at an average price of $227.42, for a total transaction of $11,011,448.98. Following the completion of the transaction, the director owned 20,342 shares in the company, valued at approximately $4,626,177.64. The trade was a 70.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 343,280 shares of company stock worth $73,566,011 in the last ninety days. 5.63% of the stock is currently owned by insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.